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ABSTRACT
Objectives: Human urate transporter 1 (URAT1) is a
member of the organic anion transporter family
(SLC22A12) that primarily regulates the renal tubular
reabsorption of uric acid. This case–control study was
designed to analyse whether hURAT1 might also be a
candidate gene for hyperuricaemia or hypouricaemia.
Setting: We recruited 68 healthy volunteers and
divided them into two groups: a normal uric acid
group and a hyperuricaemia group. We analysed the
sequence of the URAT1 gene and found five significant
single nucleotide polymorphisms (SNPs). We then
selected 900 male subjects from the 262 200 enrolled
in the Korean Cancer Prevention Study-II (KCPS-II)
cohort for further genetic analysis.
Participants: DNA samples from 36 individuals with
normal uric acid (<4.5 mg/dL) and 32 individuals with
hyperuricaemia (>8.5 mg/dL) were sequenced. Five
significant SNPs (rs7929627, rs75786299, rs3825017,
rs11602903 and rs121907892) were identified. We
then chose 900 subjects from the KCPS-II cohort
consisting of 450 subjects with normal uric acid (UA
<4.1 mg/dL) and 450 subjects with hyperuricaemia
(UA >8.7 mg/dL). The groups were matched by age,
body mass index, metabolic syndrome and use of anti-
hypertensive medication.
Primary outcome measures: We compared the OR
of the incidence of hyperuricaemia by URAT1 genotype.
Results: The strongest association with
hyperuricaemia was observed for rs75786299 (IVS3
+11A/G) with an OR of 32.05. rs7929627 (IVS7-103A/
G) and rs3825017 (N82N) showed an association with
hyperuricaemia with ORs of 2.56 and 2.29, respectively.
rs11602903 (788A/T) and rs121907892 (W258X) were
negatively correlated with hyperuricaemia with ORs of
0.350 and 0.447, respectively. Individuals carrying the
GATAG haplotype (n=32)—a relatively common variant
consisting of rs7929627, rs75786299 and rs3825017
—showed the highest risk for hyperuricaemia with an
OR of 92.23 (p=9.55×10−3).
Conclusions: These results indicate that five newly
described SNPs in the hURAT1 gene are significantly
associated with uric acid level (4-2008-0318 and 4-
2011-0277).
INTRODUCTION
Uric acid is the ﬁnal metabolic product of
purine nucleotides in humans. An elevated
level of serum uric acid is a risk factor for
gout.1 Uric acid is produced primarily in the
liver, and two-thirds of it is excreted via the
kidney. A deﬁcit in uric acid excretion results
in hyperuricaemia, leading to diseases such as
gout. On the other hand, an increase in uric
acid excretion causes urolithiasis. The uric
acid transport system of renal proximal
tubules plays an important role in the deter-
mination of serum uric acid levels.1 Uric acid
enters the proximal tubules in its anion form.
In humans, uric acid is almost fully reab-
sorbed through the kidney; only 10% of ﬁl-
tered acid is secreted.2 Absence of the
enzyme uricase and the presence of an effect-
ive renal anion transport system contribute to
higher uric acid levels in humans than in
other mammals.3 4 Uric acid serum level in
the general population follows a normal dis-
tribution.1 The intake of purines or fructose
may inﬂuence serum uric acid level. Genetic
factors may explain the critical process of uric
acid reabsorption and its role in hyperuricae-
mia. The heritability of uric acid serum con-
centration has previously been estimated to
be 40–70%.5 6 Strong evidence of this can be
seen in studies7 and segregation analysis in
Strengths and limitations of this study
▪ This study provides new understanding of
asymptomatic hyperuricaemia observed during
clinical trial screenings or regular medical
checkups.
▪ This study was well powered and well controlled:
900 subjects selected from the Korean Cancer
Prevention Study-II cohort, were divided into a
hyperuricaemia group (n=450) and a normal
group (n=450), and matched for age, body mass
index, metabolic syndrome and use of anti-
hypertensive medication.
▪ The result of this study is limited to healthy
Korean subjects with hyperuricaemia.
▪ Longitudinal and disease-course studies are
needed to evaluate the relevance of URAT1 SNPs
in gout and other metabolic diseases.
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families.8 Kottgen et al9 recently reported that 28 genetic
loci could explain the observed 6% variance in uric acid
in European Caucasian subjects. The most inﬂuential
loci, as one might expect, encode proteins involved in
secretion and renal ﬁltration of uric acid. Since Enomoto
et al10 identiﬁed the urate transporter in the human
kidney (URAT1, encoded by SLC22A12), a urate–anion
exchanger localised on the apical side of the proximal
tubule, many genome-wide association studies (GWAS)
and target SNP studies have found signiﬁcant polymorph-
isms in different ethnic groups.11–15 The most frequent
mutation, W258X for hypouricaemia, and other
hypouricaemia-related SNPs in Japanese patients, were
not found in German or Czech Caucasians subjects.16 17
It is well known that W258X (rs121907892) is associated
with hypouricaemia in Korean individuals.12 Recently, a
high frequency of SLC22A12 variants (c.1245_1253del
and c.1400C>T; 1.87% and 5.56%, respectively) which
contribute to renal hypouricaemia was reported in the
Roma population.18 Our aim was to clarify the association
of URAT1 with serum uric acid in Korean subjects. In this
study, we conducted full direct sequencing in 68 healthy
Korean subjects (36 with uric acid levels below 4.5 mg/
dL (0.076 µmol/L) and 32 with uric acid levels above
8.5 mg/dL (0.14 µmol/L)). After selection of a tagging
SNP, we validated the ﬁve signiﬁcant URAT1 SNPs in 900
men chosen from the Korean Cancer Prevention Study-II
(KCPS-II) cohort.
MATERIALS AND METHODS
Discovery of URAT1 variants by direct sequencing
Sixty-eight male genomic DNA samples were selected
from healthy individuals from the DNA bank of
Severance hospital, Seoul, Korea (4-2008-0318) taking
into account uric acid level (36 subjects with levels below
4.5 mg/dL (0.076 µmol/L) and 32 subjects with levels
above 8.0 mg/dL (0.13 µmol/L)). Ethics approval was
obtained from Severance institutional review board and
all participants provided informed consent. The health
status of each individual was evaluated by routine physical
examination and laboratory tests. Participants were
divided into two groups: a normal uric acid group that
included hypouricaemic individuals, and a hyperuricae-
mia group. To identify genetic variants of URAT1, the
entire 5802 bp URAT1 gene including the coding region,
ﬂanking intronic sequences and 30UTR region was ampli-
ﬁed and sequenced using an automated genetic analyzer
(Applied Biosystems, Foster City, California, USA).
Haplotype assembly was performed using the programme
Haploview (V.4.2; developed by the Broad Institute,
Cambridge, Massachusetts, USA). Nucleotide location
numbers were assigned from the translational start site
(GenBank accession number: AB071863).
SNP selection
Study-speciﬁc association analyses for sequencing the
data of the 68 subjects were performed using linear
regression for uric acid, assuming an additive genetic
model. For uric acid, the covariates were age and body
mass index (BMI). Excluding SNPs of less than 1%
allele frequency, we selected eight SNPs as tagging SNPs
with high linkage disequilibrium (LD) (r2>0.8). Among
these eight SNPs, ﬁve URAT1 SNPs signiﬁcant for uric
acid were selected as candidate SNPs for the replication
cohort.
Data collection of replication cohort
The KCPS-II cohort consisted of 262 200 participants
who were given routine health examinations at health
promotion centres in South Korea from 1994 to 2012.
Baseline data were collected by trained interviewers.
Information on socio-demographic factors, health status
and lifestyle was included in the questionnaires. A
general health examination was performed at the same
time. Standing height, body weight and waist circumfer-
ence were measured with participants wearing light
indoor clothing and without shoes. BMI was calculated
as weight in kilograms divided by height in metres
squared. For each individual, blood was drawn after at
least 8 h of fasting for whole blood and serum samples.
Uric acid, creatinine, triglyceride, total cholesterol, low
density lipoprotein (LDL) cholesterol, high density lipo-
protein (HDL) cholesterol and blood glucose levels
were measured using an Hitachi-7600 analyzer. Nine
hundred male subjects were selected from the KCPS-II
cohort according to the following criteria: (1) 450 sub-
jects with a uric acid level below 4.1 mg/dL (normal
group including hypouricaemia) and 450 subjects with a
uric acid level above 8.7 mg/dL (hyperuricaemia
group); and (2) age, BMI and subjects with metabolic
syndrome or taking anti-hypertensive drugs were equally
distributed into the two separate groups. All 900 subjects
agreed to provide DNA samples (4-2011-0277). To opti-
mise the effect of the URAT1 SNPs, other factors affect-
ing uric acid were balanced between the two groups.
Association analysis
After ensuring demographic similarity between the two
groups (table 1), we estimated the effects of ﬁve signiﬁ-
cant URAT1 SNPs on uric acid as an OR using a multi-
variate binary logistic regression method. BMI, systolic
blood pressure, diastolic blood pressure, total choles-
terol, triglyceride, fasting glucose, LDL cholesterol, HDL
cholesterol and creatinine are included as covariates.
Pearson’s χ2 test was used to calculate the allelic risk of
hyperuricaemia. The data were analysed using SPSS
software V.18 (SPSS, Chicago, Illinois, USA). In general,
p values of <0.05 were considered statistically signiﬁcant,
but we used adjusted p values based on the Bonferroni
correction when we performed multiple statistical tests
simultaneously.
Haplotype association analysis
Haplotype imputation by expectation maximisation was
performed in PLINK to produce the most likely
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haplotype calls. These data were then used to perform a
BMI, systolic blood pressure, diastolic blood pressure,
total cholesterol, triglyceride, fasting glucose, LDL chol-
esterol, HDL cholesterol and creatinine-adjusted logistic
regression in PLINK, producing ORs and p values.
Locus-specific hyperuricaemia genetic risk score and
correlation with uric acid level
We used the simple count method to calculate the
genetic risk score (GRS) of ﬁve URAT1 SNPs. In case of
loss-of-function URAT1 polymorphism, a score of 3 was
assigned to those homozygous for the reference allele, 2
to heterozygotes, and 1 to those homozygous for the
loss-of-function allele. In case of gain-of-function URAT1
polymorphism, 1 was assigned to those with the refer-
ence allele, 2 to heterozygotes, and 3 to those homozy-
gous for the gain-of-function allele. In this study the
GRS ranges from 3 to 15. Subjects were divided into
four groups of 225 each based on GRS score, from low
to high. The GRS distribution of the four groups was:
0<GRS<5.0, 5.0≤GRS<6.0, 6.0≤GRS<7.0 and 7.0≤GRS.
Where the hyperuricaemia group and the normal group
had the same GRS, we estimated the incremental GRS
quintile effect on hyperuricaemia versus the normal
ratio with reference to the Q1 group. The attenuation of
the association of GRS of the hyperuricaemia group
versus the normal group in a balanced demographic
sampling from the cohort suggests a causal association
between URAT1 SNPs and uric acid.19
RESULTS
URAT1 SNP discovery and association analysis with uric
acid
Whole sequencing of URAT1 was performed in 68 male
Korean subjects, divided into a hyperuricaemia group and
a normal control group (including hypouricaemia).
Sequencing revealed 26 SNPs in the URAT1 gene
(table 2). Our study is the ﬁrst to identify one SNP in the
promoter region (c.-46G>A) and three non-coding var-
iants (c.506+32T>C, c.662-18C>G and c.1395-105C>T) of
URAT1. Excluding mono call error, we conducted a correl-
ation analysis of 26 URAT1 SNPs with uric acid (data not
shown). We plotted 19 URAT1 SNPs, excluding SNPs of
less than 1% allele frequency. From 19 SNPs, we selected
eight SNPs as tagging SNPs with high LD (r2>0.8). The
eight SNPs are rs11602903, rs7929627, rs476037,
rs373337426, rs75786299, rs148845071, rs3825017 and
Table 1 Demographic characteristics
Characteristics Normal uric acid group High uric acid group Total
Discovery stage n=36 n=32 n=68
Age, years 28±4 28±3 28±4
BMI, kg/m2 24.00±2.01 22.24±2.19 23.07±2.27
Uric acid, mg/dL* 3.91±0.64
(0.066±0.011 µmol/L)
8.71±0.77
(0.15±0.013 µmol/L)
6.17±2.51
(0.10±0.042 µmol/L)
Replication stage n=450 n=450 n=900
Age, years 44±8 44±8 44±8
BMI, kg/m2* 27.18±1.96 27.53±2.19 27.35±2.09
Waist circumference, cm 91.70±6.08 92.39±6.12 92.04±6.10
Blood pressure, mm Hg
Systolic* 124.90±12.54 127.80±13.66 126.31±13.18
Diastolic* 79.96±9.21 81.84±9.63 80.90±9.47
Smoking status
Never smokers, n (%) 103 (25.06) 112 (13.69) 215 (26.28)
Ever smokers, n (%) 308 (74.94) 295 (72.48) 603 (73.72)
Alcohol consumption
Never drinkers, n (%) 50 (11.99) 54 (13.20) 104 (12.59)
Ever drinkers, n (%) 367 (88.01) 355 (86.80) 722 (87.41)
Uric acid, mg/dL* 3.59±0.47
(0.060±0.0079 µmol/L)
9.45±0.57
(0.16±0.0096 µmol/L)
6.52±2.98
(0.11±0.050 µmol/L)
Total cholesterol, mg/dL* 201.00±35.00 213.90±36.00 207.45±36.07
Triglycerides, mg/dL* 198.60±112.90 248.40±143.30 223.50±131.11
Fasting glucose, mg/dL* 110.70±41.40 96.59±13.97 103.63±31.67
LDL cholesterol, mg/dL* 118.50±33.20 126.50±35.12 122.61±34.41
HDL cholesterol, mg/dL* 47.78±10.84 45.63±9.02 46.71±10.02
Creatinine, mg/dL* 1.07±0.15 1.26±0.26 1.16±0.23
Values are mean±SD for continuous data.
*p<0.05, comparing the normal uric acid level group (<4.5 mg/dL (<0.076 µmol/L) (discovery stage) and < 4.1 mg/dL (<0.069 µmol/L)
(replication stage)) and high uric acid level group (>8.5 mg/dL (>0.14 µmol/L) (discovery stage) and >8.7 mg/dL (>0.15 µmol/L) (replication
stage)).
Body mass index (BMI) was calculated as weight in kilograms divided by height in metres squared.
HDL, high density lipoprotein; LDL, low density lipoprotein.
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rs121907892. rs11602903 represents rs974313, rs3825016,
rs3825018, rs524023, rs11231825, rs1529909, rs2021860
and rs559946. rs7929627 represents rs11231837 and
rs7932775. rs476037 represents rs3832794. Five tagging
SNPs (rs7929627, rs75786299, rs3825017, rs11602903 and
rs121907892) signiﬁcantly associated with uric acid were
selected for replication.
Genotype associations and allelic associations
We examined the relationship between the ﬁve selected
URAT1 SNPs and hyperuricaemia incidence in the dis-
covery and replication stage of this study (table 3). All
ﬁve selected SNPs showed a signiﬁcant (p<0.05) associ-
ation with uric acid level in the discovery stage (data not
shown). In the replication stage, it was observed that
subjects heterozygous or homozygous for rs7929627
were more likely to be hyperuricaemic than those in the
control group (OR=2.41, 95% CI 1.79 to 3.22,
p=3.57×10−9 and OR=7.86, 95% CI 4.85 to 12.7,
p=3.33×10−14, respectively). Subjects heterozygous for
rs75786299 were more likely to be hyperuricaemic than
those in the control group (OR=33.22, 95% CI 4.51 to
244.43, p=9.30×10−9). Subjects heterozygous or homozy-
gous for rs3825017 were more likely to be hyperuricae-
mic than those in the control group (OR=2.38, 95% CI
1.76 to 3.20, p=1.07×10−8 and OR=4.23, 95% CI 1.96 to
9.11, p=1.12×10−4, respectively). Subjects heterozygous
or homozygous for rs11602903 were less likely to be
hyperuricaemic than those in the control group
(OR=0.25, 95% CI 0.19 to 0.34, p=1.70×10−14 and
OR=0.17, 95% CI 0.10 to 0.29, p=1.93×10−12,
respectively).
Three SNPs (rs7929627, rs75786299 and rs3825017)
were associated with a gain-of-function mutation
(OR=2.37, p=0.015; OR=1.09, p=0.016; and OR=3.13,
p=0.009; rs7929627, rs75786299 and rs382501, respect-
ively) in the discovery stage. All three showed the same
results in the replication phase (OR=2.56, p=3.84×10−14;
OR=32.07, p=1.20×10−8; and OR=2.29, p=3.44×10−11;
rs7929627, rs75786299 and rs3825017, respectively).
Individuals who had the rs75786299 polymorphism
showed the highest OR for hyperuricaemia. Two SNPs
(rs11602903 and rs121907892) were associated with a
loss-of-function mutation (OR=0.45, p=0.048 and
OR=0.915, p=0.017; rs11602903 and rs121907892,
respectively). These two SNPs induced hypouricaemia
(rs11602903, rs121907892; OR=0.350, p=3.60×10−14 and
OR=0.447, p=1.10×10−14, respectively) in the replication
cohort as well.
Haplotype association analysis
We performed logistic regression analysis to evaluate the
association between the incidence of hyperuricaemia
and haplotype of the ﬁve selected SNPs with reference
to the AGCAG haplotype. Haplotype AGCAG SNPs are
rs7929627, rs75786299, rs3825017, rs11602903 and
rs121907892. Haplotype GGCAG contains one
gain-of-function SNP, rs7929627, and is associated with a
signiﬁcantly increased incidence of hyperuricaemia
(p=0.035; OR=1.48). Haplotype GGTAG contains two
gain of function SNPs, rs7929627 and rs3825017, and is
associated with a signiﬁcantly increased incidence of
hyperuricaemia (p=0.011; OR=1.64). Haplotype GATAG
contains three gain-of-function SNPs, rs7929627,
rs75786299 and rs3825017, and is associated with a sig-
niﬁcantly increased incidence of hyperuricaemia
(p=9.55×10−3; OR=92.23). Haplotype AGCAA contains
one loss-of-function SNP, rs121907892, and is associated
Table 2 Frequency of URAT1 genetic variations in Korean subjects
rs number Variant
Amino acid
substitution
Minor allele
frequency rs number Variant
Amino acid
substitution
Minor allele
frequency
Promoter variants
rs11602903 c.-788A>T 0.265 rs559946 c.-424C>T 0.265
rs524023 c.-764C>T 0.265 rs3825018 c.-220A>G 0.265
rs9734313 c.-718C>T 0.265 – c.-46G>A 0.007
Coding variant
rs3825017 c.246C>T N82N 0.224 rs121907893 c.650C>T T217M 0.007
rs3825016 c.258C>T H86H 0.265 rs121907892 c.774G>A W258X 0.044
rs11231825 c.426T>C H142H 0.265 rs7932775 c.1309T>C L437L 0.427
Non-coding variants
– c.506+32T>C 0.007 rs78880801 c.1070+66C>T 0.008
rs75786299 c.661+11G>A 0.037 rs373337426 c.1071-33C>T 0.022
– c.662-18C>G 0.007 rs7929627 c.1286-103A>G 0.427
rs2021860 c.830+109G>T 0.265 – c.1395-105C>T 0.007
rs1529909 c.831-45T>C 0.273 rs11231837 c.1598+18C>T 0.427
30UTR variants
rs139299506 c.*163delTC 0.007 rs3832794 c.*291delG 0.316
rs148845071 c.*268G>A 0.037 rs476037 c.*517G>A 0.316
Data were obtained from DNA samples from 68 unrelated Korean individuals.
The position of the variant is based upon the translational start site.
4 Cho SK, et al. BMJ Open 2015;5:e009360. doi:10.1136/bmjopen-2015-009360
Open Access
Table 3 Allele association of five tagged SNPs in the normal group and hyperuricaemia group in the replication cohort
SNP amino acid change
(rs number) Genotype
Normal uric
acid group
High uric
acid group
Allele frequency
Allele OR (95% CI) p ValueControl Case
Discovery stage UA <4.5 mg/dL
(<0.076 µmol/L)
UA >8.5 mg/dL
(>0.14 µmol/L)
IVS7-103A/G (rs7929627) AA 17 7 0.32 0.53 2.37 (1.18 to 4.76)
(R: A)
0.015
AG 14 16
GG 5 9
IVS3+11A/G (rs75786299) GG 36 27 0 0.08 1.09 (1.01 to 1.17)
(R: G)
0.016
GA 0 5
N82N (rs3825017) CC 27 13 0.13 0.31 3.13 (1.30 to 7.52)
(R: C)
0.009
CT 9 17
TT 0 2
-788A/T (rs11602903) AA 15 21 0.34 0.19 0.452 (0.204 to 1.003)
(R: A)
0.048
AT 18 10
TT 3 1
W258X (rs121907892) GG 30 32 0.09 0 0.915 (0.853 to 0.983)
(R: G)
0.017
GA 6 0
AA 0 0
Replication stage UA < 4.1 mg/dL
(<0.076 µmol/L)
UA >8.7 mg/dL
(<0.076 µmol/L)
IVS7-103A/G (rs7929627) AA 236 119 0.27 0.48 2.56 (2.10 to 3.12) (R: A) 3.84×10−14
AG 188 228
GG 26 103
IVS3+11A/G (rs75786299) GG 449 419 <0.01 0.03 32.07 (4.37 to 235.44)
(R: G)
1.20×10−8
GA 1 31
N82N (rs3825017) CC 345 254 0.13 0.25 2.29 (1.78 to 2.93)
(R: C)
3.44×10−11
CT 96 168
TT 9 28
-788A/T (rs11602903) AA 136 292 0.42 0.20 0.350 (0.284 to 0.432)
(R: A)
3.60×10−14
AT 253 136
TT 61 22
W258X (rs121907892) GG 282 450 0.19 0 0.447 (0.424 to 0.472)
(R: G)
1.10×10−14
GA 164 0
AA 4 0
p Value is determined by Pearson’s χ2 test in the allele analysis.
R, reference allele.
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with the absence of hyperuricaemia. Haplotype AGCTA
contains two loss-of-function SNPs, rs11602903 and
rs121907892, and is associated with the absence of
hyperuricaemia. Haplotypes AGCTG and GGCTG were
not signiﬁcantly different from the reference haplotype.
Gout GRS association
A simple GRS was calculated to determine the cumula-
tive effect of the URAT1 SNPs. In each set, the incidence
of hyperuricaemia was signiﬁcantly higher than the GRS
of the control group (Q1) (table 4). We found a correl-
ation between GRS and incidence of hyperuricaemia
(Q1 vs Q2, Q1 vs Q3 and Q1 vs Q4; OR=4.00,
p=2.00×10−6; OR=5.78, p=4.50×10−10; and OR=15.62,
p=1.94×10−25, respectively).
DISCUSSION
We found signiﬁcant uric acid-related URAT1 SNPs that
differed between hyperuricaemic and normal or hypour-
icaemic subjects. Five selected SNPs from the discovery
stage showed a signiﬁcant association with uric acid in
the 900 replication cohort subjects. In the haplotype
analysis, the OR for the incidence of hyperuricaemia
was gradually increased when an individual carried one
gain-of-function SNP, two SNPs or three SNPs (OR=1.48,
1.64 and 92.23 respectively). On the other hand, the OR
decreased when an individual had one loss-of-function
SNP or two such SNPs (OR=0.86 and 0, respectively).
Finally, we investigated the effect of URAT1 on uric acid
using GRS analysis (table 4).
Founder mutation rs12190789220 showed the strongest
association with hypouricaemia in our study. In the repli-
cation cohort, the uric acid level in individuals homozy-
gous (AA) for rs121907892 was 1.85±0.17 mg/dL (0.031
±0.0029 µmol/L), while the uric acid of subjects homo-
zygous (AA) for rs121907892 was below 2 mg/dL
(0.034 µmol/L). Interestingly, Korean subjects with the
rs11602903 allele were at an increased risk for hypouri-
caemia, whereas Graessler et al16 reported that the AA
genotype of rs11602903 in German subjects was asso-
ciated with reduced renal uric acid excretion (OR=1.8,
95% CI 1.129 to 2.993, p=0.0139 for fractional excretion
of uric acid). Decreased renal uric acid excretion
implies increased URAT1 activity, which should correlate
with higher uric acid levels. Considering the difference
in allele frequency in the two ethnic groups, the risk
associated with the allele is comparable. Li et al,21 study-
ing a Chinese population, showed that people with the
rs11602903 allele had an increased incidence of hypour-
icaemia. Our tagging SNP, rs7929627, a SNP in intron 7,
is genetically identical to rs7932775, a SNP in exon
8. Han Chinese individuals carrying rs7932775 were at
increased risk for hyperuricaemia.21 A recent report on
a Caucasian Czech population did not show any signiﬁ-
cant difference in serum uric acid level associated with
rs7932775. Since our replication set focused instead on
rs7929627, it is difﬁcult to explain this discrepancy
between studies in Caucasian and Asian populations.
Further investigation is needed.
Although rs3825017 was not signiﬁcantly associated
with uric acid levels in the Chinese study,21 it showed a
strong association in our study (OR=2.29, 95% CI 1.78 to
2.93, p=3.44×10−11). Because the population size of the
present study was much larger, it is likely that we observed
real effects that would not otherwise have been statistic-
ally signiﬁcant. rs75786299 is the SNP most strongly asso-
ciated with hyperuricaemia in our study (OR=32.07, 95%
CI 4.37 to 235.44, p=3.44×10−11). Because of its low allelic
frequency (1.8% in Korean subjects), this SNP was not
identiﬁed by any previous GWAS study. Further func-
tional study is needed to conﬁrm our results, although
Lee et al12 investigated the prevalence of hypouricaemia
and its association with two URAT1 SNPs (W258X and
R90H) in healthy Korean subjects. To the best our knowl-
edge, this is the ﬁrst study to sequence the entire URAT1
gene and investigate these ﬁve tagging SNPs and their
association with uric acid levels in Korean subjects.
Our study has some limitations. First, we could not ﬁnd
previously identiﬁed missense and frame shift mutations
with lower allelic frequencies: R90H, V138M, G164S and
T217M.16 This may be explained by population selection as
we did not recruit patients with nephrolithiasis and low uric
acid. Further study is needed to investigate patients with
nephrolithiasis and low uric acid to demonstrate consistency
with the previous report.20 Second, we could not evaluate
all of the signiﬁcant SNPs from the discovery stage. Since
coverage of our ﬁve tagged SNPs is in the high LD region
(r2=0.8), other SNPs might show different results in the rep-
lication stage. However, we are conﬁdent that these ﬁve
selected SNPs convincingly illustrate an association of
URAT1 with uric acid level in Korean subjects. Third, our
study results have not been conﬁrmed in patients with gout
or nephrolithiasis. A logical next step is to investigate
URAT1 SNP association with gout and nephrolithiasis.
We conclude that the haplotype association of our ﬁve
selected URAT1 SNPs with hyperuricaemia has a poten-
tial predictive beneﬁt. We found the hyperuricaemia
related variant in the combined analysis (GATAG;
OR=92.23, p=0.0096), which is associated with a high
risk of gout in Korean subjects. We also found the
hypouricaemic related variant (AGCTA), which is asso-
ciated with a high risk for nephrolithiasis.20 To validate a
Table 4 Adjusted ORs and 95% CIs for the
hyperuricaemia group versus the normal group ratio by
genetic risk score (GRS) of URAT1 SNP among 900
subjects
GRS
quartile OR 95% CI p Value
p For
trend
Q1 1.00
Q2 4.00 2.26 to 7.08 2.00×10−6
Q3 5.78 3.33 to 10.04 4.50×10−10 1.18×10−31
Q4 15.62 9.32 to 26.19 1.94×10−25
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genetic marker for future risk prediction for gout or
nephrolithiasis, a large data association study is required
that investigates the prevalence of our SNPs in gout
patients or subjects who have had kidney stones.
Contributors SKC, J-YC, SHJ: participated in research design; SKC, SK:
conducted the study; SKC, SK, J-YC: performed data analysis; SKC, SK, J-YC,
SHJ: wrote or contributed to the writing of the manuscript.
Funding This study was supported by the Seoul City R & BD programme (grant
no. 10526) and grants (A111218-PG03) from the National Project for Personalized
Genomic Medicine under the Ministry for Health and Welfare of the Republic of
Korea. We appreciate the kind support of Eunsoon Shin, DNA Link, Inc.
Competing interests None declared.
Patient consent Obtained.
Ethics approval Severance hospital institutional review board approved this
study.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. Riches PL, Wright AF, Ralston SH. Recent insights into the
pathogenesis of hyperuricaemia and gout. Hum Mol Genet 2009;18:
R177–84.
2. Anzai N, Kanai Y, Endou H. New insights into renal transport of
urate. Curr Opin Rheumatol 2007;19:151–7.
3. Bobulescu IA, Moe OW. Renal transport of uric acid: evolving
concepts and uncertainties. Adv Chronic Kidney Dis
2012;19:358–71.
4. Wu XW, Muzny DM, Lee CC, et al. Two independent mutational
events in the loss of urate oxidase during hominoid evolution. J Mol
Evol 1992;34:78–84.
5. Nath SD, Voruganti VS, Arar NH, et al. Genome scan for
determinants of serum uric acid variability. J Am Soc Nephrol
2007;18:3156–63.
6. Yang Q, Guo C, Cupples LA, et al. Genome-wide search for genes
affecting serum uric acid levels: the Framingham Heart Study.
Metabolism 2005;54:1435–41.
7. Emmerson BT, Nagel SL, Duffy DL, et al. Genetic control of the
renal clearance of urate: a study of twins. Ann Rheum Dis
1992;51:375–7.
8. Wilk JB, Djousse L, Borecki I, et al. Segregation analysis of serum
uric acid in the NHLBI Family Heart Study. Hum Genet
2000;106:355–9.
9. Kottgen A, Albrecht E, Teumer A, et al. Genome-wide association
analyses identify 18 new loci associated with serum urate
concentrations. Nat Genet 2013;45:145–54.
10. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular
identification of a renal urate anion exchanger that regulates blood
urate levels. Nature 2002;417:447–52.
11. Zar ZM, Eloranta J, Stieger B, et al. Pharmacogenetics of OATP
(SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15)
transporters in the intestine, liver and kidney. Pharmacogenomics
2008;9:597–624.
12. Lee JH, Choi HJ, Lee BH, et al. Prevalence of hypouricaemia and
SLC22A12 mutations in healthy Korean subjects. Nephrology
(Carlton) 2008;13:661–6.
13. Takahashi T, Tsuchida S, Oyamada T, et al. Recurrent URAT1 gene
mutations and prevalence of renal hypouricemia in Japanese.
Pediatr Nephrol 2005;20:576–8.
14. Jang WC, Nam Y, Park S, et al. T6092C polymorphism of
SLC22A12 gene is associated with serum uric acid
concentrations in Korean male subjects. Clin Chim Acta
2008;398:140–4.
15. Shafiu M, Johnson RJ, Turner ST, et al. Urate transporter gene
SLC22A12 polymorphisms associated with obesity and metabolic
syndrome in Caucasians with hypertension. Kidney Blood Press Res
2012;35:477–82.
16. Graessler J, Graessler A, Unger S, et al. Association of the human
urate transporter 1 with reduced renal uric acid excretion and
hyperuricemia in a German Caucasian population. Arthritis Rheum
2006;54:292–300.
17. Hurba O, Mancikova A, Krylov V, et al. Complex analysis of urate
transporters SLC2A9, SLC22A12 and functional characterization of
non-synonymous allelic variants of GLUT9 in the Czech population:
no evidence of effect on hyperuricemia and gout. PLoS ONE
2014;9:e107902.
18. Gabrikova D, Bernasovska J, Sokolova J, et al. High frequency of
SLC22A12 variants causing renal hypouricemia 1 in the
Czech and Slovak Roma population; simple and rapid detection
method by allele-specific polymerase chain reaction. Urolithiasis
2015;2:2.
19. Lawlor DA, Harbord RM, Sterne JA, et al. Mendelian randomization:
using genes as instruments for making causal inferences in
epidemiology. Stat Med 2008;27:1133–63.
20. Ichida K, Hosoyamada M, Hisatome I, et al. Clinical and molecular
analysis of patients with renal hypouricemia in Japan-influence of
URAT1 gene on urinary urate excretion. J Am Soc Nephrol
2004;15:164–73.
21. Li C, Han L, Levin AM, et al. Multiple single nucleotide
polymorphisms in the human urate transporter 1 (hURAT1) gene are
associated with hyperuricaemia in Han Chinese. J Med Genet
2010;47:204–10.
Cho SK, et al. BMJ Open 2015;5:e009360. doi:10.1136/bmjopen-2015-009360 7
Open Access
